 |
|
Carbon 11–Labeled Pittsburgh Compound B and Carbon 11–Labeled (R)-PK11195 Positron Emission Tomographic Imaging in Alzheimer Disease
Clayton A. Wiley, MD, PhD;
Brian J. Lopresti, BS;
Sriram Venneti, MD, PhD;
Julie Price, PhD;
William E. Klunk, MD, PhD;
Steven T. DeKosky, MD;
Chester A. Mathis, PhD
Arch Neurol. 2009;66(1):60-67.
Background Alzheimer disease (AD) is defined neuropathologically by the presence of neurofibrillary tangles and plaques associated with tau and β-amyloid protein deposition. The colocalization of microglia and β-amyloid plaques has been widely reported in pathological examination of AD and suggests that neuroinflammation may play a role in pathogenesis and/or progression. Because postmortem histopathological analyses are limited to single end-stage assessment, the time course and nature of this relationship are not well understood.
Objective To image microglial activation and β-amyloid deposition in the brains of subjects with and without AD.
Design, Setting, and Participants Using two carbon 11 ([11C])–labeled positron emission tomographic imaging agents, Pittsburgh Compound B (PiB) and (R)-PK11195, we examined the relationship between amyloid deposition and microglial activation in different stages of AD using 5 control subjects, 6 subjects diagnosed with mild cognitive impairment, and 6 patients with mild to moderate AD.
Results Consistent with prior reports, subjects with a clinical diagnosis of probable AD showed significantly greater levels of [11C]PiB retention than control subjects, whereas patients with mild cognitive impairment spanned a range from control-like to AD-like levels of [11C]PiB retention. Additionally, 2 asymptomatic control subjects also exhibited evidence of elevated PiB retention in regions associated with the early emergence of plaques in AD and may represent prodromal cases of AD. We observed no differences in brain [11C](R)-PK11195 retention when subjects were grouped by clinical diagnosis or the presence or absence of β-amyloid pathological findings as indicated by analyses of [11C]PiB retention.
Conclusions These findings suggest that either microglial activation is limited to later stages of severe AD or [11C](R)-PK11195 is too insensitive to detect the level of microglial activation associated with mild to moderate AD.
Author Affiliations: Departments of Pathology (Drs Wiley and Venneti), Radiology (Mr Lopresti and Drs Price and Mathis), Psychiatry (Dr Klunk), and Neurology (Dr DeKosky), University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Dr Venneti is now with the Department of Pathology, University of Pennsylvania, Philadelphia.
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
This Month in Archives of Neurology
Arch Neurol. 2009;66(1):17-18.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Evidence for Astrocytosis in Prodromal Alzheimer Disease Provided by 11C-Deuterium-L-Deprenyl: A Multitracer PET Paradigm Combining 11C-Pittsburgh Compound B and 18F-FDG
Carter et al.
JNM 2012;53:37-46.
ABSTRACT
| FULL TEXT
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray and Rogers
Cold Spring Harb Perspect Med 2012;2:a006346-a006346.
ABSTRACT
| FULL TEXT
In Vivo Positron Emission Tomographic Imaging of Glial Responses to Amyloid-{beta} and Tau Pathologies in Mouse Models of Alzheimer's Disease and Related Disorders
Maeda et al.
J. Neurosci. 2011;31:4720-4730.
ABSTRACT
| FULL TEXT
Microglia: Key Innate Immune Cells of the Brain
Kofler and Wiley
Toxicol Pathol 2011;39:103-114.
ABSTRACT
| FULL TEXT
Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease
Kadir et al.
Brain 2011;134:301-317.
ABSTRACT
| FULL TEXT
Radioisotopic Imaging of Neuroinflammation
Winkeler et al.
JNM 2010;51:1-4.
ABSTRACT
| FULL TEXT
|
